Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

Final Appraisal Recommendation

Advice number: 1522 – September 2022

Dupilumab (Dupixent®) 200 mg and 300 mg solution for injection in pre-filled syringe or pre-filled pen

Submission by Sanofi

Recommendation of the All Wales Medicines Strategy Group

Dupilumab (Dupixent®) is recommended as an option for restricted use within NHS Wales.

Dupilumab (Dupixent®) is licensed in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.

Dupilumab (Dupixent®) is restricted for use in a subpopulation of the licensed indication in line with the National Institute of Health and Care Excellence recommendation for the restricted use of dupilumab for treating severe asthma with type 2 inflammation (TA751).

Dupilumab (Dupixent®) is not recommended for use within NHS Wales outside of this subpopulation.

This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the posology of dupilumab (Dupixent®) in children aged 6-11 years.
- Please refer to the Summary of Product Characteristics for the full licensed indication.
- See NICE guidance for dupilumab (Dupixent®) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over (TA751, originally published December 2021).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 4017), which includes the All Wales Toxicology and Therapeutics Centre (AWTTC) assessment form, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review after three years.